Coral Labs.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE683E01017
NSEID:
BSEID: 524506

INR

463.40

-6.35 (-1.35%)

BSENSE

Dec 05

BSE+NSE Vol: 703

{
  "main_header": {
    "sid": 476417,
    "name": "Coral Labs.",
    "stock_name": "Coral Labs.",
    "full_name": "Coral Laboratories Ltd",
    "name_url": "stocks-analysis/coral-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "463.40",
    "chg": -6.35,
    "chgp": "-1.35%",
    "dir": -1,
    "prev_price": "469.75",
    "mcapval": "168.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524506,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE683E01017",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "703 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/coral-labs-476417-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Coral Labs. Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-labs-upgraded-from-strong-sell-to-sell-by-marketsmojo-on-27-oct-2025-3746329",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/CoralLabs_mojoScore_3746329.png",
        "date": "2025-12-04 11:08:46",
        "description": "Coral Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued market performance and sector dynamics."
      },
      {
        "title": "Why is Coral Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-coral-labs-fallingrising-3744950",
        "imagepath": "",
        "date": "2025-12-04 00:43:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Coral Laboratories’ share price has been under pressure, registering a loss of 3.56% over the past week compared to a modest 0.59% decline in the Sensex. The divergence becomes more pronounced over the last month, with the stock falling 4.51% while the Sensex gained 1.34%. Year-to-date figures reveal a stark contrast: Coral Labs has declined by 38.05%, whereas the Sensex has appreciated by 8.92%. Over the last year, the stock’s performance has been even more subdued, down 41.00% against the Sensex’s 5.27% rise. These figures highlight a sustained period of underperformance relative to the benchmark index.</p>\n<p>Despite this, the company’s longer-term returns over three and five years remain positive, with gains of 48.98% and 48.13%..."
      },
      {
        "title": "Coral Laboratories Q2 FY26: Sharp Revenue Decline Raises Concerns Despite Margin Recovery",
        "link": "https://www.marketsmojo.com/news/result-analysis/coral-laboratories-q2-fy26-sharp-revenue-decline-raises-concerns-despite-margin-recovery-3718966",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CoralLaboratori_quaterlyResult_3718966.png",
        "date": "2025-11-18 16:59:45",
        "description": "Coral Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹178.00 crores, reported concerning quarterly results for Q2 FY26, with net profit standing at ₹5.82 crores, representing a sequential increase of 127.34% from Q1 FY26's ₹2.56 crores, but a year-on-year decline of 8.78% from ₹6.38 crores in Q2 FY25. The stock has underperformed significantly over the past year, declining 34.70% whilst the Sensex gained 9.48%, resulting in a negative alpha of 44.18 percentage points."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3709750",
        "imagepath": "",
        "date": "2025-11-18 08:20:34",
        "description": "As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers.\n\nIn comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex...."
      },
      {
        "title": "How has been the historical performance of Coral Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-coral-labs-3703296",
        "imagepath": "",
        "date": "2025-11-14 23:54:07",
        "description": "Answer:\nThe historical performance of Coral Labs shows a significant upward trend in net sales and profitability over the past few years.\n\nBreakdown:\nCoral Labs has demonstrated a strong growth trajectory in net sales, increasing from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. The company's operating profit (PBDIT) excluding other income surged from 3.81 Cr in March 2023 to 26.24 Cr in March 2025, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 8.23 Cr in March 2023 to 32.47 Cr in March 2025, while profit after tax increased from 6.45 Cr to 24.16 Cr in the same period. The earnings per share (EPS) also saw a substantial rise from 18.07 in March 2023 to 67.68 in March 2025, showcasing enhanced shareholder value. On the ba..."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3700062",
        "imagepath": "",
        "date": "2025-11-14 08:08:25",
        "description": "As of 13 November 2025, Coral Labs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 9.66, a Price to Book Value of 0.89, and an EV to EBITDA of 4.22. These ratios indicate a strong valuation position compared to its peers, particularly when contrasted with Sun Pharma's PE ratio of 36.15 and Divi's Lab's PE ratio of 70.4, both of which are significantly higher.\n\nThe company's financial metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. With a ROCE of 24.89% and a PEG ratio of 0.00, Coral Labs demonstrates efficient capital utilization and growth potential. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -34.52% compared to the Sensex's 8.11%, the underlying fundamentals suggest that Coral Labs is a compelling investment opportunity at its cu..."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3696048",
        "imagepath": "",
        "date": "2025-11-13 08:09:02",
        "description": "As of 12 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 10.04, an EV to EBITDA of 4.62, and a Price to Book Value of 0.92, which are significantly lower than many of its peers. For instance, Sun Pharma has a PE ratio of 35.94 and Divi's Lab has a PE ratio of 69.64, both categorized as expensive, indicating that Coral Labs is trading at a more favorable valuation relative to these competitors.\n\nIn addition to the favorable ratios, Coral Labs shows a strong ROCE of 24.89% and ROE of 9.18%, suggesting efficient use of capital. The company's recent stock performance has been mixed, with a year-to-date return of -31.95%, contrasting sharply with the Sensex's positive return of 8.10% over the same period. This underperformance may present a buying opportunity, given the company's solid f..."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3668647",
        "imagepath": "",
        "date": "2025-11-04 08:06:23",
        "description": "As of 3 November 2025, Coral Labs. has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued, given its compelling financial ratios, including a PE Ratio of 9.59, an EV to EBITDA of 4.15, and a Price to Book Value of 0.88. These figures suggest that Coral Labs. is trading at a significant discount compared to its peers in the pharmaceuticals and biotechnology sector.\n\nIn comparison, Sun Pharma. Inds. is deemed expensive with a PE Ratio of 35.62, while Cipla is rated attractive with a PE Ratio of 22.44. The PEG Ratio for Coral Labs. stands at 0.00, indicating strong growth potential relative to its price. Despite recent stock performance lagging behind the Sensex, particularly in the year-to-date and one-year periods, the underlying valuation metrics suggest that Coral Labs. presents a favorable investment opportunity...."
      },
      {
        "title": "Is Coral Labs. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coral-labs-overvalued-or-undervalued-3660226",
        "imagepath": "",
        "date": "2025-10-31 08:08:35",
        "description": "As of 30 October 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE Ratio of 9.83, an EV to EBITDA of 4.40, and a Price to Book Value of 0.90, all of which suggest that the stock is trading at a discount compared to its peers.\n\nIn comparison to its industry, Coral Labs' PE Ratio is significantly lower than that of Sun Pharma, which stands at 35.63, and Divi's Lab at 76.52, both categorized as expensive. Additionally, while Coral Labs has a PEG Ratio of 0.00, indicating potential growth at a low price, peers like Cipla and Dr. Reddy's Labs, both rated attractive, have PEG Ratios of 1.28 and 2.15, respectively. Despite recent underperformance against the Sensex over the past year, Coral Labs' strong ratios suggest it remains a compelling investment opportunity...."
      }
    ],
    "total": 134,
    "sid": "476417",
    "stock_news_url": "https://www.marketsmojo.com/news/coral-laboratories-476417"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14 2025 Pursuant To Regulation 30 (Read With Part A Of Schedule III) The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)",
      "datetime": "14-Nov-2025",
      "details": "The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended September 30 2025 and took note of the Limited Review Report submitted by S C Mehra & Associates LLP Statutory Auditor of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Results - Financial Results For Quarter And Half Year Ended September 30 2025",
      "datetime": "14-Nov-2025",
      "details": "The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended September 30 2025 and took note of the Limited Review Report submitted by S C Mehra & Associates LLP Statutory Auditor of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Notice Under Regulation 29(1) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "07-Nov-2025",
      "details": "Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Pursuant to Regulation 29(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the meeting of the Board of Directors of the Company has been scheduled to be held on Friday November 14 2025 at Registered Office of Company at 3 B Patanwala Compound Opp Shreyas Cinema L.B.S. Marg Ghatkopar West Mumbai- 400086 inter alia for the following business(es): ? To consider and adopt the unaudited standalone financial results statement of asset & liabilities and statement of cash flow for the quarter and half year ended on September 30 2025 with limited review report thereon in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. ? Any other business with the permission of chairman.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Coral Laboratories Ltd has declared <strong>15%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Coral Labs. Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-12-04 11:08:46

Coral Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued market performance and sector dynamics.

Why is Coral Labs. falling/rising?

2025-12-04 00:43:55

Recent Price Movement and Market Comparison

Coral Laboratories’ share price has been under pressure, registering a loss of 3.56% over the past week compared to a modest 0.59% decline in the Sensex. The divergence becomes more pronounced over the last month, with the stock falling 4.51% while the Sensex gained 1.34%. Year-to-date figures reveal a stark contrast: Coral Labs has declined by 38.05%, whereas the Sensex has appreciated by 8.92%. Over the last year, the stock’s performance has been even more subdued, down 41.00% against the Sensex’s 5.27% rise. These figures highlight a sustained period of underperformance relative to the benchmark index.

Despite this, the company’s longer-term returns over three and five years remain positive, with gains of 48.98% and 48.13%...

Coral Laboratories Q2 FY26: Sharp Revenue Decline Raises Concerns Despite Margin Recovery

2025-11-18 16:59:45

Coral Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹178.00 crores, reported concerning quarterly results for Q2 FY26, with net profit standing at ₹5.82 crores, representing a sequential increase of 127.34% from Q1 FY26's ₹2.56 crores, but a year-on-year decline of 8.78% from ₹6.38 crores in Q2 FY25. The stock has underperformed significantly over the past year, declining 34.70% whilst the Sensex gained 9.48%, resulting in a negative alpha of 44.18 percentage points.

Is Coral Labs. overvalued or undervalued?

2025-11-18 08:20:34

As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers. In comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex....

How has been the historical performance of Coral Labs.?

2025-11-14 23:54:07

Answer: The historical performance of Coral Labs shows a significant upward trend in net sales and profitability over the past few years. Breakdown: Coral Labs has demonstrated a strong growth trajectory in net sales, increasing from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. The company's operating profit (PBDIT) excluding other income surged from 3.81 Cr in March 2023 to 26.24 Cr in March 2025, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 8.23 Cr in March 2023 to 32.47 Cr in March 2025, while profit after tax increased from 6.45 Cr to 24.16 Cr in the same period. The earnings per share (EPS) also saw a substantial rise from 18.07 in March 2023 to 67.68 in March 2025, showcasing enhanced shareholder value. On the ba...

Is Coral Labs. overvalued or undervalued?

2025-11-14 08:08:25

As of 13 November 2025, Coral Labs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 9.66, a Price to Book Value of 0.89, and an EV to EBITDA of 4.22. These ratios indicate a strong valuation position compared to its peers, particularly when contrasted with Sun Pharma's PE ratio of 36.15 and Divi's Lab's PE ratio of 70.4, both of which are significantly higher. The company's financial metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. With a ROCE of 24.89% and a PEG ratio of 0.00, Coral Labs demonstrates efficient capital utilization and growth potential. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -34.52% compared to the Sensex's 8.11%, the underlying fundamentals suggest that Coral Labs is a compelling investment opportunity at its cu...

Is Coral Labs. overvalued or undervalued?

2025-11-13 08:09:02

As of 12 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 10.04, an EV to EBITDA of 4.62, and a Price to Book Value of 0.92, which are significantly lower than many of its peers. For instance, Sun Pharma has a PE ratio of 35.94 and Divi's Lab has a PE ratio of 69.64, both categorized as expensive, indicating that Coral Labs is trading at a more favorable valuation relative to these competitors. In addition to the favorable ratios, Coral Labs shows a strong ROCE of 24.89% and ROE of 9.18%, suggesting efficient use of capital. The company's recent stock performance has been mixed, with a year-to-date return of -31.95%, contrasting sharply with the Sensex's positive return of 8.10% over the same period. This underperformance may present a buying opportunity, given the company's solid f...

Is Coral Labs. overvalued or undervalued?

2025-11-04 08:06:23

As of 3 November 2025, Coral Labs. has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued, given its compelling financial ratios, including a PE Ratio of 9.59, an EV to EBITDA of 4.15, and a Price to Book Value of 0.88. These figures suggest that Coral Labs. is trading at a significant discount compared to its peers in the pharmaceuticals and biotechnology sector. In comparison, Sun Pharma. Inds. is deemed expensive with a PE Ratio of 35.62, while Cipla is rated attractive with a PE Ratio of 22.44. The PEG Ratio for Coral Labs. stands at 0.00, indicating strong growth potential relative to its price. Despite recent stock performance lagging behind the Sensex, particularly in the year-to-date and one-year periods, the underlying valuation metrics suggest that Coral Labs. presents a favorable investment opportunity....

Is Coral Labs. overvalued or undervalued?

2025-10-31 08:08:35

As of 30 October 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE Ratio of 9.83, an EV to EBITDA of 4.40, and a Price to Book Value of 0.90, all of which suggest that the stock is trading at a discount compared to its peers. In comparison to its industry, Coral Labs' PE Ratio is significantly lower than that of Sun Pharma, which stands at 35.63, and Divi's Lab at 76.52, both categorized as expensive. Additionally, while Coral Labs has a PEG Ratio of 0.00, indicating potential growth at a low price, peers like Cipla and Dr. Reddy's Labs, both rated attractive, have PEG Ratios of 1.28 and 2.15, respectively. Despite recent underperformance against the Sensex over the past year, Coral Labs' strong ratios suggest it remains a compelling investment opportunity....

View All News

Announcement

Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14 2025 Pursuant To Regulation 30 (Read With Part A Of Schedule III) The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)

14-Nov-2025 | Source : BSE

The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended September 30 2025 and took note of the Limited Review Report submitted by S C Mehra & Associates LLP Statutory Auditor of the Company.

Results - Financial Results For Quarter And Half Year Ended September 30 2025

14-Nov-2025 | Source : BSE

Board Meeting Intimation for Notice Under Regulation 29(1) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015

07-Nov-2025 | Source : BSE

Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Pursuant to Regulation 29(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the meeting of the Board of Directors of the Company has been scheduled to be held on Friday November 14 2025 at Registered Office of Company at 3 B Patanwala Compound Opp Shreyas Cinema L.B.S. Marg Ghatkopar West Mumbai- 400086 inter alia for the following business(es): ? To consider and adopt the unaudited standalone financial results statement of asset & liabilities and statement of cash flow for the quarter and half year ended on September 30 2025 with limited review report thereon in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. ? Any other business with the permission of chairman.